Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

eculizumab

A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:alexion
eculizumab biosimilar ABP 959
eculizumab biosimilar BCD-148
eculizumab biosimilar SB12
immunoglobulin, anti-(human complement C5 alpha-chain) (human-mouse monoclonal 5G1.1 heavy chain), disulfide with human-mouse monoclonal 5G.1.1 light chain, dimer
monoclonal antibody 5G1.1
monoclonal antibody anti-C5
US brand name:Elizaria
Soliris
Abbreviation:h5G1.1
Code name:ABP 959
ABP-959
ABP959
BCD 148
BCD-148
BCD148
SB 12
SB-12
SB12
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search